The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Results for Pembrolizumab as a First-Line Therapy for Advanced Urothelial Carcinoma

Arjun Balar, MD
Published Online:2:17 PM, Mon May 22, 2017

Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discussed results of the KEYNOTE-052 study of pembrolizumab (Keytruda) as a first-line therapy for patients with cisplatin-ineligible advanced urothelial cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.